Cell therapy plus tafasitamab for autoimmune diseases
Treatments studied
Part of Immune system & allergy, Kidney & urinary, Lungs & breathing, Skin, Women’s health & pregnancy clinical trials.
This trial tests a new cell therapy (AD-PluReceptor) combined with the drug tafasitamab for people with certain autoimmune diseases like systemic sclerosis, lupus, or chronic graft-versus-host disease. It aims to see if this treatment can help when standard therapies have failed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have one of these autoimmune diseases: systemic sclerosis, lupus, or chronic graft-versus-host disease.
- For systemic sclerosis: your disease started within the last 7 years and you have either high skin thickening scores or lung scarring that has gotten worse despite treatment.
- For lupus: your lupus is active (including kidney inflammation) and has not responded to at least two standard treatments.
- For chronic GVHD: your condition is moderate to severe and has not responded to two standard therapies (ruxolitinib and belumosudil).
- You must be between 18 and 80 years old and have adequate organ function (like blood counts, kidney and liver function).
- You cannot have had prior CAR T-cell therapy, active infections, or certain heart conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new cell therapy called YTS109 for people with several autoimmune diseases that have not improved with standard medications. It aims to see if this treatment can help control the disease when other treatments have failed.
This trial tests a new type of immune therapy called CAR T-cells that target two markers on your B cells (CD19 and BCMA). It is for people with certain autoimmune diseases that have not improved or have come back after standard treatments. The goal is to see if this therapy can help control the disease.
This trial tests if a special immune cell therapy (CAR-T) can help people with certain autoimmune diseases like lupus, Sjogren's syndrome, scleroderma, myositis, vasculitis, or antiphospholipid syndrome that haven't improved with standard treatments. It is a very early phase study to check safety and effectiveness.
This trial tests a new CAR-T cell treatment for people with certain autoimmune diseases that have not responded to standard therapies. The treatment uses your own immune cells modified to target and attack disease-causing cells.
This trial tests a new cell therapy called YTS109 for people with severe autoimmune diseases like lupus, Sjögren's syndrome, systemic sclerosis, inflammatory myopathy, vasculitis, and antiphospholipid syndrome. It's for those whose disease hasn't improved with standard treatments.
This trial tests a new treatment using your own immune cells (called CAR-T cells) designed to target and attack cells that cause autoimmune diseases. It is for people with lupus, Sjögren's syndrome, inflammatory myopathy, scleroderma, Behcet's disease, ANCA-associated vasculitis, IgG4-related disease, antiphospholipid syndrome, or thrombotic thrombocytopenic purpura who have not improved with standard therapies.
Hear when a new Autoimmune Disorders trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.